Expected launch of news NASH treatments will drive huge market growth, says analyst

Although no treatments are currently approved for non-alcoholic steatohepatitis (NASH), quite a number or compounds are progressing in clinical development that hopefully will change this situation, and lead to strong market growth.

The total size of the NASH market across the seven leading markets is set to expand from just $138.4 million in 2016 to $18.3 billion in 2026 at a compound annual growth rate (CAGR) of 63%, according to data and analytics company GlobalData.

The company’s latest report: ‘ Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026’ states that a high level of unmet need for drugs in NASH, coupled with the expected launch of many new products across the 7MM (USA, Germany, France, Italy, Spain, the UK, and Japan), will drive huge levels of growth in the NASH market.

Thomas Moore, senior pharma analyst at GlobalData, says: “There are currently no therapeutic options approved to treat patients with NASH, meaning there is high unmet need for drugs which are able to manage this potentially life-threatening condition. As a result, any new drug which is proven to help patients with NASH is expected to see rapid uptake, and generate significant market growth.”